Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice
Ruklanthi de Alwis, Esther S. Gan, Shiwei Chen, et al.
Molecular Therapy (2021) Vol. 29, Iss. 6, pp. 1970-1983
Open Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

Lipid nanoparticles for mRNA delivery
Xucheng Hou, Tal Zaks, Róbert Langer, et al.
Nature Reviews Materials (2021) Vol. 6, Iss. 12, pp. 1078-1094
Open Access | Times Cited: 2197
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 984
Nanomaterial Delivery Systems for mRNA Vaccines
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 457
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 415
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 409
Lipids and Lipid Derivatives for RNA Delivery
Yuebao Zhang, Changzhen Sun, Chang Wang, et al.
Chemical Reviews (2021) Vol. 121, Iss. 20, pp. 12181-12277
Open Access | Times Cited: 392
Self-assembled mRNA vaccines
Jeonghwan Kim, Yulia Eygeris, Mohit Gupta, et al.
Advanced Drug Delivery Reviews (2021) Vol. 170, pp. 83-112
Open Access | Times Cited: 379
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 310
COVID-19: A review of therapeutic strategies and vaccine candidates
Vladislav Izda, Matlock A. Jeffries, Amr H. Sawalha
Clinical Immunology (2020) Vol. 222, pp. 108634-108634
Open Access | Times Cited: 274
mRNA vaccines for COVID-19: what, why and how
Jung Woo Park, Philip N.P. Lagniton, Yu Liu, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 6, pp. 1446-1460
Open Access | Times Cited: 273
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Daniel Martínez-Flores, Jesús Zepeda–Cervantes, Adolfo Cruz-Reséndiz, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 218
COVID-19: Coronavirus Vaccine Development Updates
Jing Zhao, Shan Zhao, Junxian Ou, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 212
An Update on Self-Amplifying mRNA Vaccine Development
Anna K. Blakney, Shell Ip, Andrew J. Geall
Vaccines (2021) Vol. 9, Iss. 2, pp. 97-97
Open Access | Times Cited: 195
The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape
Dandan Tian, Yanhong Sun, Jianming Zhou, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 192
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Michael J. Hogan, Norbert Pardi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 17-39
Open Access | Times Cited: 186
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Yuta Suzuki, Hiroshi Ishihara
Drug Metabolism and Pharmacokinetics (2021) Vol. 41, pp. 100424-100424
Open Access | Times Cited: 183
Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines
Despo Chatzikleanthous, Derek T. O’Hagan, Roberto Adamo
Molecular Pharmaceutics (2021) Vol. 18, Iss. 8, pp. 2867-2888
Open Access | Times Cited: 112
mRNA vaccines in disease prevention and treatment
Gang Zhang, Tianyu Tang, Yinfeng Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 109
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
Jamile Ramos da Silva, Karine Bitencourt Rodrigues, Guilherme Formoso Pelegrin, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 686
Open Access | Times Cited: 77
Research Advances on the Stability of mRNA Vaccines
Feiran Cheng, Yi‐Ping Wang, Yu Bai, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 668-668
Open Access | Times Cited: 66
Recent Advancement in mRNA Vaccine Development and Applications
Nojoud AL Fayez, Majed S. Nassar, Abdullah A. Alshehri, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1972-1972
Open Access | Times Cited: 64
Circular RNA in cancer
Vanessa M. Conn, Arul M. Chinnaiyan, Simon J. Conn
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 597-613
Closed Access | Times Cited: 36
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials
Nhân Thị Hồ, Steven G. Hughes, Van Thanh Ta, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 31
Frameworks for transformational breakthroughs in RNA-based medicines
John R. Androsavich
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 421-444
Closed Access | Times Cited: 22
Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency
Joshua E. McGee, Jack R. Kirsch, Devin Kenney, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top